ArticleACS nano2022
Designer Liposomic Nanocarriers Are Effective Biofilm Eradicators.
Article in ACS nano, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 36 citations in OpenAlex.
- PMPCylated liposomes in drug delivery and beyond.Materials today. Bio · 2026Review
- Protease-assisted microencapsulation of carvacrol in pea protein systems for enhanced and durable antibiofilm activity.Current research in food science · 2026Article
- Polymicrobial Biofilms: Interkingdom Interactions, Resistance and Therapeutic Strategies.Microbial biotechnology · 2025Review
- A novel tetrahedral framework nucleic acid-based antibiotic delivery system: overcoming biofilm barriers to combat chronic infections.Journal of nanobiotechnology · 2025Article
- Liposome-encapsulated antibiotics and biosurfactants: an effective strategy to boost biofilm eradication in cooling towers.Microbial cell factories · 2025Article
- In Situ Application of Berberine-Loaded Liposomes on the Treatment of Osteomyelitis.ACS omega · 2025Article
- Liposome-Assisted Drug Delivery in the Treatment of Multiple Sclerosis.Molecules (Basel, Switzerland) · 2024Review
- Article
- Bacteriophage-mediated approaches for biofilm control.Frontiers in cellular and infection microbiology · 2024Review
- Liposomes-Based Drug Delivery Systems of Anti-Biofilm Agents to Combat Bacterial Biofilm Formation.Antibiotics (Basel, Switzerland) · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug delivery via nanovehicles is successfully employed in several clinical settings, yet bacterial infections, forming microbial communities in the form of biofilms, present a strong challenge to therapeutic treatment due to resistance to conventional antimicrobial therapies. Liposomes can provide a versatile drug-vector strategy for biofilm treatment, but are limited by the need to balance colloidal stability with biofilm penetration. We have discovered a liposomic functionalization strategy, using membrane-embedded moieties of poly[2-(methacryloyloxy)ethyl phosphorylcholine], pMPC, that overcomes this limitation. Such pMPCylation results in liposomic stability equivalent to current functionalization strategies (mostly PEGylation, the present gold-standard), but with strikingly improved cellular uptake and cargo conveyance. Fluorimetry, cryo-electron, and fluorescence microscopies reveal a far-enhanced antibiotic delivery to model
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.